Cardiome Pharma Corp. (CRME) Stock Price & Overview

NASDAQ:CRME

Current stock price

2.33
-0.05 (-2.1%)
Last:

The current stock price of CRME is 2.33 null. Today CRME is down by -2.1%. In the past month the price decreased by -1.69%. In the past year, price decreased by -44.52%.

CRME Key Statistics

52-Week Range1.29 - 4.84
Current CRME stock price positioned within its 52-week range.
1-Month Range2.06 - 2.45
Current CRME stock price positioned within its 1-month range.
Market Cap
81.247M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.90
Dividend Yield
N/A

CRME Stock Performance

Today
-2.1%
1 Week
+1.30%
1 Month
-1.69%
3 Months
+58.50%
Longer-term
6 Months +71.32%
1 Year -44.52%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CRME Stock Chart

Cardiome Pharma Corp. / CRME Daily stock chart

CRME Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to CRME. When comparing the yearly performance of all stocks, CRME turns out to be only a medium performer in the overall market: it outperformed 65.17% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
CRME Full Technical Analysis Report

CRME Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CRME. Both the profitability and financial health of CRME have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CRME Full Fundamental Analysis Report

CRME Earnings

Next Earnings DateN/A
Last Earnings DateN/A
CRME Earnings History

CRME Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y14.44%
Revenue Next YearN/A
CRME Forecast & Estimates

CRME Financial Highlights

Over the last trailing twelve months CRME reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS decreased by -13.92% compared to the year before.


Income Statements
Revenue(TTM)25.35M
Net Income(TTM)-31.94M
Industry RankSector Rank
PM (TTM) -125.98%
ROA -54.06%
ROE -351.31%
Debt/Equity 4.31
Chartmill High Growth Momentum
EPS Q2Q%-33.33%
Sales Q2Q%25.85%
EPS 1Y (TTM)-13.92%
Revenue 1Y (TTM)8.5%
CRME financials

CRME Ownership

Ownership
Inst Owners50.49%
Shares34.87M
FloatN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
CRME Ownership

About CRME

Company Profile

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.

Company Info

Cardiome Pharma Corp.

1441 Creekside Drive 6th Floor

Vancouver A1 V6J 4S7

CEO: William L. Hunter

Phone: 604-677-6905

Cardiome Pharma Corp. / CRME FAQ

What does Cardiome Pharma Corp. do?

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function.


What is the stock price of Cardiome Pharma Corp. today?

The current stock price of CRME is 2.33 null. The price decreased by -2.1% in the last trading session.


What is the dividend status of Cardiome Pharma Corp.?

CRME does not pay a dividend.


What is the ChartMill technical and fundamental rating of CRME stock?

CRME has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the market capitalization of CRME stock?

Cardiome Pharma Corp. (CRME) has a market capitalization of 81.25M null. This makes CRME a Micro Cap stock.